Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282317 | 0.89 | CRBN (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12638348 | 0.87 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768175 | 0.87 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768176 | 0.85 | DDB1 (0.50) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768178 | 0.83 | DDB1 (0.48) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768179 | 0.82 | DDB1 (0.48) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12638377 | 0.80 | DDB1 (0.46) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15745529 | 0.77 | CRBN (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19525976 | 0.76 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20437026 | 0.76 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION | 2015-06-04 | — | — | US | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | DDB1 2526/4885CRBN 2562/4885IKZF3 3719/4885 |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | DDB1 4060/4885CRBN 3139/4885IKZF3 4145/4885 |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.